MAIA BIOTECHNOLOGY INC
MAIANYSE AMERICANπ #4050 by market capEarnings Mar 22 Β· PostUS Equity
$1.11βΌ $0.03 (β2.63%)
Market closed Β· at closeTrack MAIA
Get earnings, price moves & breaking news on Telegram
24hβΌ 2.6%
7dβ² 11.0%
14dβ² 5.7%
30dβΌ 3.5%
ytdβΌ 26.5%
1yβ² 21.8%
π¦Market Cap
$69M
Small Cap
πRevenue Growth (YoY)
β
πGross Margin
β
π΅FCF Margin
β
βοΈP/S Ratio
β
Otter Score
β
Insufficient data
Trading Snapshot
- Day Range
- $1.09 β $1.14
- 52-Week Range
- $0.87 β $3.19
- Volume (shares)
- 498,730
- Avg Volume (shares)
- β
- Shares Outstanding
- 61.7M
- Next Earnings
- 2027-03-22
Fundamentals Snapshot
- Annual Revenue
- β
- Last Q Revenue
- β
- P/E Ratio
- β
- P/S Ratio
- β
- EPS (TTM)
- $-0.64
- Dividend Yield
- β
- Dilution (1yr)
- +22.8%
MAIA BIOTECHNOLOGY INC
MAIAFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isnβt profitable yet.
β$24Mβ² +43.1% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
β$19Mβ² +20.0% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing ownerβs slice.
32.1Mβ² +22.8% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$9MβΌ β$943K YoY
About MAIA BIOTECHNOLOGY INC
MAIA Biotechnology, Inc. is a clinical-stage biotech firm dedicated to discovering, developing, and commercializing treatments for various cancers, with a primary focus on non-small cell lung cancer. The company's leading experimental compound, THIO, is an investigational drug candidate that utilizes a unique dual mechanism by targeting telomeres and stimulating an immune response. Established in 2018, the enterprise maintains its headquarters in Chicago, Illinois.
π¦¦
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
π§Dilutionβ
β
β
β
β
Overall Score
Insufficient data
β/100
Analyst Ratings
βConsensus
Buy
7 analysts
Strong Buy2
Buy4
Hold1
Sell0
Strong Sell0
Ratings as of Nov 2026
Latest News & Updates
News unavailable.